New Phase III patiromer data boost Relypsa's IPO prospects
This article was originally published in Scrip
Executive Summary
Relypsa upped its chances for a successful launch into the US stock market on 10 October when president and CEO John Orwin said the company plans to file for US FDA approval of the hyperkalemia drug candidate patiromer (RLY5016) based on statistically significant results from Part B of a Phase III clinical trial. Relypsa, which has the only therapy in development to treat high potassium levels in the blood, believes that its data support chronic dosing.